|
WO2021038532A1
|
|
Novel formulation of highly concentrated pharmacologically active antibody
|
|
WO2021038487A2
|
|
Compounds useful to treat pain
|
|
WO2021009669A2
|
|
A process for separation and quantitation of proteins using capillary electrophoresis
|
|
WO2020257250A1
|
|
Gastroretentive dosage forms of levodopa and carbidopa
|
|
WO2020181127A1
|
|
Delayed release methylphenidate compositions
|
|
US2020222310A1
|
|
Pharmaceutical composition comprising eliglustat
|
|
WO2020061308A1
|
|
Extended release compositions comprising trihexyphenidyl
|
|
US2019388351A1
|
|
Extended release compositions comprising pyridostigmine
|
|
EP3628004A1
|
|
Self-regulating osmotic gastroretentive drug delivery systems
|
|
US2019374473A1
|
|
Extended release compositions comprising pyridostigmine
|
|
US2021069117A1
|
|
Extended release compositions comprising pyridostigmine
|
|
CA3101421A1
|
|
Prodrugs of fulvestrant
|
|
WO2019211778A2
|
|
Pro-drugs of eliglustat
|
|
WO2019211708A1
|
|
Stable pharmaceutical compositions of dianhydrogalactitol
|
|
WO2019186450A1
|
|
Ulipristal acetate derivatives
|
|
EP3735228A1
|
|
Programmable pharmaceutical compositions for chrono drug release
|
|
EP3735238A1
|
|
A stable oral pharmaceutical composition of ferric citrate
|
|
US2016346274A1
|
|
Abuse-resistant drug formulations with built-in overdose protection
|
|
US2016317530A1
|
|
Abuse-resistant drug formulations
|
